| HOME >> BIOLOGY >> TECHNOLOGY |
TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. The Company announced today that JPI's subsidiary JJB received an updated third party valuation of its land use rights, plant and buildings that have been now been reappraised for a total of approximately $21.8 million, significantly above the FY2007 book value of these assets.
Frank Zheng, Managing Director of Jade, stated that "This new appraisal by the accounting firm of Jiangxi Zhong Cheng Accounting Co., Ltd., is anticipated to provide JJB with the ability to significantly expand its current credit facilities, including gaining larger credit facilities under more favorable interest rates."
Mr. Gary Dreher, CEO of AMDL noted that "this new appraisal is another illustration of the significant value that JPI's business brings to AMDL in 2008 and beyond."
About Jade Pharmaceutical Inc.: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statem
'/>"/>
| SOURCE AMDL, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |